ReviewInternational journal of clinical oncology2026
Skin toxicity induced by chemotherapy or molecular targeted therapy combined with immune checkpoint inhibitors in Asian patients: A literature review by the Japanese Pharmacist-led Oncodermatology Study Team.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundCombination therapy with immune checkpoint inhibitors (ICIs) and cytotoxic or targeted anticancer agents has improved survival in multiple cancers but may exacerbate drug-related skin toxicities. These toxicities share inflammatory mechanisms, and ICI-induced immune cell infiltration into the skin may increase both their incidence and severity. This review evaluated the impact of adding ICIs on skin toxicities in adult Asian patients.
methodsPubMed was searched for English-language clinical trials published between January 2014 and September 2025 using the keywords "immune checkpoint inhibitor" and "clinical study." Randomized controlled trials involving adult Asian patients treated with ICIs in combination with cytotoxic chemotherapy or molecularly targeted therapy were included.
resultsOf 7287 identified articles, 28 met inclusion criteria. Studies assessed capecitabine-induced hand-foot syndrome (HFS), multikinase inhibitor-induced hand-foot skin reaction (HFSR), taxane-induced alopecia, and epidermal growth factor receptor (EGFR) inhibitor-related skin toxicities. The incidence of capecitabine-related HFS (11/13 articles) and EGFR inhibitor-related skin toxicities (1/1 article) tended to be higher with the addition of ICIs.
conclusionsWhile ICIs have substantially improved survival outcomes, their immunomodulatory effects may amplify drug-specific dermatologic toxicities when used in combination regimens. Shared inflammatory pathways and immune cell recruitment to the skin likely underlie this interaction, underscoring the importance of anticipatory monitoring and optimized management strategies in combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.